Navigation Links
To combat deadly brain cancer, target the stem cells
Date:7/7/2011

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found in glioma stem cells that allows them to grow and seed tumors. Importantly, normal stem cells, including those in the brain, don't appear to share that same dependency.

"When thinking about therapeutics [targeting cancer stem cells], you have to be careful that you aren't interfering with normal stem cells," said Christine Eyler of the Cleveland Clinic. "Glioma stem cells are not derived from normal stem cells but they do share many features with them. The trick to therapy is to find pathways exhibited only by cancer stem cells."

The goal of Eyler's team, led by Cleveland Clinic scientist Jeremy Rich, was to identify just such a pathway in glioma stem cells, a particularly devastating form of brain cancer. Despite modern surgical and medical therapies, those diagnosed with a glioblastoma have a median survival of just over a year.

Previous work identifying glioma cells with stem-cell like behavior and demonstrating the propagation of gliomas in animals offered hope for the development of anti-glioma therapeutics. The challenge, however, has been finding pathways that differ between glioma and normal stem cells in spite of evidence that the glioma stem cells closely resemble embryonic and neural stem cells.

Earlier studies led the researchers to investigate the pathway that produces nitric oxide (NO), a molecule thought to support tumors' growth and resistance to treatment. Those experiments showed that glioma cells express varying levels of nitric oxide synthases, critical enzymes in that pathway.

"It's important to note that there are different forms of nitric oxide synthases," said Anita Hjelmeland, also at the Cleveland Clinic. "We focused on one that is well restricted to glioma stem cells."

In the current study, the authors use mouse models of glioma to show that glioma stem cells have elevated levels of nitric oxide synthase-2 (NOS2). This leads to exess production of NO, which, in turn, endows stem cells with the ability to growand seed tumors.

These findings have real clinical relevance, the researchers say. They found that high NOS2 levels correlate with decreased survival in patients with glioma. Moreover, treatments designed to block NOS2 in the brain slow the growth of brain tumors in mice.

Notably, NOS2 inhibitors have already been tested in clinical trials for other treatments. "The exciting part is the drugs have already been given to people," Eyler said, and it appears they have little toxicity.

NOS2 inhibitors could be a welcome addition to therapies in use for gliomas today. "If you target the tumor as a whole, you may get rid of most cells but leave the stem cells behind," Hjelmeland said. But if you only target cancer stem cells and leave the rest intact, tumors may continue to grow. By combining approaches, "you'll have a better therapy."

Eyler said she wouldn't be surprised if the nitric oxide pathway uncovered in glioma stem cells might also prove to be important in other forms of cancer. The researchers also continue to look for other pathways unique to cancer stem cells.


'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Video games may help combat depression in older adults
2. National Hispanic Council on Aging Joins the Administration in Mission to Combat Medicare Fraud By Empowering Hispanics
3. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
4. Combat E-Cigarette in Demand by Civilians
5. The Net Impact Creates Website for St. Louis Event to Combat the Stigma of Mental Illness
6. HIV Drugs Might Combat Two Other Diseases
7. Children of combat-deployed parents show increased worries, even after parent returns
8. HealthMETRICS Partners, Inc. Article in AJMC Outlines Innovative Approach to Combat Rising Healthcare Costs
9. Holistic Management and Allan Savory Win the 2010 Buckminster Fuller Award for Turning Deserts into Thriving Grasslands and Combating Climate Change.
10. Novel Drug Combats Advanced Melanoma
11. US Army 2010 Combat Casualty Care Conference, Aug. 16-19, St. Pete Beach, Fla.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: